Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.